Hengrui Pharma, GSK enter licensing deal worth up to $12bn
GSK will obtain a global license to Hengrui Pharma’s potential PDE3/4 programme, HRS-9821, except in mainland China, Hong Kong, Macau and Taiwan.
A leading resource for the Pharmaceutical industry since 2002
GSK will obtain a global license to Hengrui Pharma’s potential PDE3/4 programme, HRS-9821, except in mainland China, Hong Kong, Macau and Taiwan.
Give your business an edge with our leading industry insights.